This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ONC392, ONC 392
Description: ONC-392 is an anti-CTLA4 monoclonal antibody.
OncoImmune and Pfizer
In September 2016, OncoImmune entered into an exclusive option and license agreement with Pfizer for ONC-392 in a deal worth up to $250 million in upfront and potential milestone payments.
Under the terms of the agreement, Pfizer plans to evaluate ONC-392 up until a certain agreed-upon time to determine whether it will exercise its option to exclusively license ONC-392 as well as any other OncoImmune anti-CTLA4 antibodies. If Pfizer exercises its option under the agreement, Pfizer would be responsible for all development and potential commercialization of the program, and OncoImmune would be eligible to receive potential developmental and commercial milestone payments as well as royalties, tiered from mid-single up to low-double digits, on sales of any potential resulting products.
Partners: OncoImmune, Inc.
Additional information available to subscribers only: